{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T02:18:59Z","timestamp":1784081939770,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"DOI":"10.1007\/s00401-025-02892-5","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T12:15:34Z","timestamp":1748866534000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Anti-pyroglutamate-3 A\u03b2 immunotherapy engages microglia and inhibits amyloid accumulation in transgenic mouse models of A\u03b2 amyloidosis"],"prefix":"10.1007","volume":"149","author":[{"given":"Fan","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Calvo-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meha","family":"Chhaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian P","family":"Sefrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik I","family":"Charych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Mezler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Clausznitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily J","family":"McGlame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp F","family":"Secker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Fernandez Garcia-Agudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy","family":"Dellovade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Karran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"2892_CR1","doi-asserted-by":"publisher","unstructured":"(2024) 2024 Alzheimer's disease facts and figures. Alzheimers Dement 20: 3708-3821 https:\/\/doi.org\/10.1002\/alz.13809","DOI":"10.1002\/alz.13809"},{"key":"2892_CR2","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/78682","volume":"6","author":"F Bard","year":"2000","unstructured":"Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H et al (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6:916\u2013919. https:\/\/doi.org\/10.1038\/78682","journal-title":"Nat Med"},{"key":"2892_CR3","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1038\/s41380-021-01409-2","volume":"27","author":"TA Bayer","year":"2022","unstructured":"Bayer TA (2022) Pyroglutamate Abeta cascade as drug target in Alzheimer\u2019s disease. Mol Psychiatry 27:1880\u20131885. https:\/\/doi.org\/10.1038\/s41380-021-01409-2","journal-title":"Mol Psychiatry"},{"key":"2892_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3233\/JAD-2011-110977","volume":"28","author":"B Bohrmann","year":"2012","unstructured":"Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F et al (2012) Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis 28:49\u201369. https:\/\/doi.org\/10.3233\/JAD-2011-110977","journal-title":"J Alzheimers Dis"},{"key":"2892_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S et al (2022) Two Randomized phase 3 studies of Aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis 9:197\u2013210. https:\/\/doi.org\/10.14283\/jpad.2022.30","journal-title":"J Prev Alzheimers Dis"},{"key":"2892_CR6","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20231363","author":"MP Cadiz","year":"2024","unstructured":"Cadiz MP, Gibson KA, Todd KT, Nascari DG, Massa N, Lilley MT et al (2024) Aducanumab anti-amyloid immunotherapy induces sustained microglial and immune alterations. J Exp Med. https:\/\/doi.org\/10.1084\/jem.20231363","journal-title":"J Exp Med"},{"key":"2892_CR7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3233\/JAD-221305","volume":"93","author":"RJ Castellani","year":"2023","unstructured":"Castellani RJ, Shanes ED, McCord M, Reish NJ, Flanagan ME, Mesulam MM et al (2023) Neuropathology of anti-amyloid-beta immunotherapy: a case report. J Alzheimers Dis 93:803\u2013813. https:\/\/doi.org\/10.3233\/JAD-221305","journal-title":"J Alzheimers Dis"},{"key":"2892_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3174\/ajnr.A8469","volume":"46","author":"PM Cogswell","year":"2025","unstructured":"Cogswell PM, Andrews TJ, Barakos JA, Barkhof F, Bash S, Benayoun MD et al (2025) Alzheimer disease anti-amyloid immunotherapies: imaging recommendations and practice considerations for monitoring of amyloid-related imaging abnormalities. AJNR Am J Neuroradiol 46:24\u201332. https:\/\/doi.org\/10.3174\/ajnr.A8469","journal-title":"AJNR Am J Neuroradiol"},{"key":"2892_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13195-019-0579-8","volume":"12","author":"H Crehan","year":"2020","unstructured":"Crehan H, Liu B, Kleinschmidt M, Rahfeld JU, Le KX, Caldarone BJ et al (2020) Effector function of anti-pyroglutamate-3 Abeta antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer\u2019s-like mice. Alzheimers Res Ther 12:12. https:\/\/doi.org\/10.1186\/s13195-019-0579-8","journal-title":"Alzheimers Res Ther"},{"key":"2892_CR10","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S et al (2023) Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis 10:362\u2013377. https:\/\/doi.org\/10.14283\/jpad.2023.30","journal-title":"J Prev Alzheimers Dis"},{"key":"2892_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","volume":"38","author":"J Cummings","year":"2024","unstructured":"Cummings J, Osse AML, Cammann D, Powell J, Chen J (2024) Anti-Amyloid monoclonal antibodies for the treatment of Alzheimer\u2019s disease. BioDrugs 38:5\u201322. https:\/\/doi.org\/10.1007\/s40259-023-00633-2","journal-title":"BioDrugs"},{"key":"2892_CR12","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","volume":"76","author":"RB Demattos","year":"2012","unstructured":"Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA et al (2012) A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer\u2019s disease mice. Neuron 76:908\u2013920. https:\/\/doi.org\/10.1016\/j.neuron.2012.10.029","journal-title":"Neuron"},{"key":"2892_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","volume":"16","author":"SM Greenberg","year":"2020","unstructured":"Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ (2020) Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. Nat Rev Neurol 16:30\u201342. https:\/\/doi.org\/10.1038\/s41582-019-0281-2","journal-title":"Nat Rev Neurol"},{"key":"2892_CR14","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/j.stemcr.2017.05.017","volume":"8","author":"W Haenseler","year":"2017","unstructured":"Haenseler W, Sansom SN, Buchrieser J, Newey SE, Moore CS, Nicholls FJ et al (2017) A highly efficient human pluripotent stem cell microglia model displays a neuronal-co-culture-specific expression profile and inflammatory response. Stem Cell Rep 8:1727\u20131742. https:\/\/doi.org\/10.1016\/j.stemcr.2017.05.017","journal-title":"Stem Cell Rep"},{"key":"2892_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2021.105365","volume":"154","author":"J Janssens","year":"2021","unstructured":"Janssens J, Hermans B, Vandermeeren M, Barale-Thomas E, Borgers M, Willems R et al (2021) Passive immunotherapy with a novel antibody against 3pE-modified Abeta demonstrates potential for enhanced efficacy and favorable safety in combination with BACE inhibitor treatment in plaque-depositing mice. Neurobiol Dis 154:105365. https:\/\/doi.org\/10.1016\/j.nbd.2021.105365","journal-title":"Neurobiol Dis"},{"key":"2892_CR16","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","volume":"21","author":"E Karran","year":"2022","unstructured":"Karran E, De Strooper B (2022) The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov 21:306\u2013318. https:\/\/doi.org\/10.1038\/s41573-022-00391-w","journal-title":"Nat Rev Drug Discov"},{"key":"2892_CR17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/jnen\/61.9.797","volume":"61","author":"WE Klunk","year":"2002","unstructured":"Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP et al (2002) Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol 61:797\u2013805. https:\/\/doi.org\/10.1093\/jnen\/61.9.797","journal-title":"J Neuropathol Exp Neurol"},{"key":"2892_CR18","doi-asserted-by":"publisher","first-page":"14156","DOI":"10.1523\/JNEUROSCI.4147-08.2008","volume":"28","author":"J Koenigsknecht-Talboo","year":"2008","unstructured":"Koenigsknecht-Talboo J, Meyer-Luehmann M, Parsadanian M, Garcia-Alloza M, Finn MB, Hyman BT et al (2008) Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J Neurosci 28:14156\u201314164. https:\/\/doi.org\/10.1523\/JNEUROSCI.4147-08.2008","journal-title":"J Neurosci"},{"key":"2892_CR19","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"JM Long","year":"2019","unstructured":"Long JM, Holtzman DM (2019) Alzheimer disease: an update on pathobiology and treatment strategies. Cell 179:312\u2013339. https:\/\/doi.org\/10.1016\/j.cell.2019.09.001","journal-title":"Cell"},{"key":"2892_CR20","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW et al (2021) Donanemab in early Alzheimer\u2019s disease. N Engl J Med 384:1691\u20131704. https:\/\/doi.org\/10.1056\/NEJMoa2100708","journal-title":"N Engl J Med"},{"key":"2892_CR21","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1126\/science.1078259","volume":"298","author":"M Pfeifer","year":"2002","unstructured":"Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M et al (2002) Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298:1379. https:\/\/doi.org\/10.1126\/science.1078259","journal-title":"Science"},{"key":"2892_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00401-022-02433-4","volume":"144","author":"ED Plowey","year":"2022","unstructured":"Plowey ED, Bussiere T, Rajagovindan R, Sebalusky J, Hamann S, von Hehn C et al (2022) Alzheimer disease neuropathology in a patient previously treated with aducanumab. Acta Neuropathol 144:143\u2013153. https:\/\/doi.org\/10.1007\/s00401-022-02433-4","journal-title":"Acta Neuropathol"},{"key":"2892_CR23","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1523\/JNEUROSCI.4337-04.2005","volume":"25","author":"MM Racke","year":"2005","unstructured":"Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK et al (2005) Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 25:629\u2013636. https:\/\/doi.org\/10.1523\/JNEUROSCI.4337-04.2005","journal-title":"J Neurosci"},{"key":"2892_CR24","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/sj.embor.7400784","volume":"7","author":"R Radde","year":"2006","unstructured":"Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L et al (2006) Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 7:940\u2013946. https:\/\/doi.org\/10.1038\/sj.embor.7400784","journal-title":"EMBO Rep"},{"key":"2892_CR25","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/0896-6273(95)90301-1","volume":"14","author":"TC Saido","year":"1995","unstructured":"Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S (1995) Dominant and differential deposition of distinct beta-amyloid peptide species, a beta N3(pE), in senile plaques. Neuron 14:457\u2013466. https:\/\/doi.org\/10.1016\/0896-6273(95)90301-1","journal-title":"Neuron"},{"key":"2892_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M et al (2016) The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease. Nature 537:50\u201356. https:\/\/doi.org\/10.1038\/nature19323","journal-title":"Nature"},{"key":"2892_CR27","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J et al (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330:512\u2013527. https:\/\/doi.org\/10.1001\/jama.2023.13239","journal-title":"JAMA"},{"key":"2892_CR28","doi-asserted-by":"publisher","first-page":"8220","DOI":"10.1038\/s41467-023-43933-5","volume":"14","author":"E Solopova","year":"2023","unstructured":"Solopova E, Romero-Fernandez W, Harmsen H, Ventura-Antunes L, Wang E, Shostak A et al (2023) Fatal iatrogenic cerebral beta-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer\u2019s disease. Nat Commun 14:8220. https:\/\/doi.org\/10.1038\/s41467-023-43933-5","journal-title":"Nat Commun"},{"key":"2892_CR29","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT et al (2011) Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s association research roundtable workgroup. Alzheimers Dement 7:367\u2013385. https:\/\/doi.org\/10.1016\/j.jalz.2011.05.2351","journal-title":"Alzheimers Dement"},{"key":"2892_CR30","doi-asserted-by":"publisher","first-page":"9993","DOI":"10.1126\/scitranslmed.adk9993","volume":"15","author":"GT Tabor","year":"2023","unstructured":"Tabor GT, Holtzman DM (2023) Current status of amyloid-targeting immunotherapies for Alzheimer\u2019s disease. Sci Transl Med 15:9993. https:\/\/doi.org\/10.1126\/scitranslmed.adk9993","journal-title":"Sci Transl Med"},{"key":"2892_CR31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13024-024-00758-0","volume":"19","author":"X Taylor","year":"2024","unstructured":"Taylor X, Noristani HN, Fitzgerald GJ, Oluoch H, Babb N, McGathey T et al (2024) Amyloid-beta (Abeta) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer\u2019s disease. Mol Neurodegener 19:77. https:\/\/doi.org\/10.1186\/s13024-024-00758-0","journal-title":"Mol Neurodegener"},{"key":"2892_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M et al (2023) Lecanemab in early Alzheimer\u2019s Disease. N Engl J Med 388:9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"key":"2892_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071098","volume":"8","author":"B van Wilgenburg","year":"2013","unstructured":"van Wilgenburg B, Browne C, Vowles J, Cowley SA (2013) Efficient, long term production of monocyte-derived macrophages from human pluripotent stem cells under partly-defined and fully-defined conditions. PLoS One 8:e71098. https:\/\/doi.org\/10.1371\/journal.pone.0071098","journal-title":"PLoS One"},{"key":"2892_CR34","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.3233\/JAD-170056","volume":"59","author":"S Villarreal","year":"2017","unstructured":"Villarreal S, Zhao F, Hyde LA, Holder D, Forest T, Sondey M et al (2017) Chronic Verubecestat treatment suppresses amyloid accumulation in advanced aged Tg2576-AbetaPPswe mice without inducing Microhemorrhage. J Alzheimers Dis 59:1393\u20131413. https:\/\/doi.org\/10.3233\/JAD-170056","journal-title":"J Alzheimers Dis"},{"key":"2892_CR35","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1523\/JNEUROSCI.5077-10.2011","volume":"31","author":"A Wang","year":"2011","unstructured":"Wang A, Das P, Switzer RC 3rd, Golde TE, Jankowsky JL (2011) Robust amyloid clearance in a mouse model of Alzheimer\u2019s disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J Neurosci 31:4124\u20134136. https:\/\/doi.org\/10.1523\/JNEUROSCI.5077-10.2011","journal-title":"J Neurosci"},{"key":"2892_CR36","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1523\/JNEUROSCI.23-09-03745.2003","volume":"23","author":"DM Wilcock","year":"2003","unstructured":"Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE et al (2003) Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci 23:3745\u20133751. https:\/\/doi.org\/10.1523\/JNEUROSCI.23-09-03745.2003","journal-title":"J Neurosci"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-025-02892-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00401-025-02892-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-025-02892-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T12:15:36Z","timestamp":1748866536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00401-025-02892-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["2892"],"URL":"https:\/\/doi.org\/10.1007\/s00401-025-02892-5","relation":{},"ISSN":["1432-0533"],"issn-type":[{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FL, MCR, JPS, EIC, MM, DC, EJM, KZ, AR, YC, LFG, LH, CK, TD are employees of AbbVie. MC, PFS and EK were AbbVie employee at the time of the study. The design, study conduct, and financial support for this research were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"55"}}